2 Years Since Marijuana Legalization: Here’s How Canada’s Top Stocks Have Done

You probably would’ve been better off avoiding Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and other pot stocks over the past couple of years.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Oct. 17, 2018, is when the recreational marijuana industry officially opened for business in Canada. It’s been a topsy-turvy time since then. Investors have seen sky-high valuations crumble over the years, and the CannTrust scandal has destroyed a lot of the confidence investors had in the industry. Bruce Linton, who’s able to put a stock on the map just by wearing its t-shirt, was arguably the icon of the industry, and he was unceremoniously removed from his position as CEO at Canopy Growth (TSX:WEED)(NYSE:CGC) over a year ago. Those are just some of the most newsworthy developments to have taken place over the past two years.

If you were bullish on the cannabis industry, you may have been tempted to invest in it. With the industry legal, there were high expectations for growth. There was just one big problem: valuations were already out of control. At more than $20 billion, Canopy Growth was grossly overvalued in 2019, as it continued to rise in the legal industry’s early stages. But a correction was overdue and as Canopy Growth tumbled, so too did its peers.

Here’s how much you’d have left on a $10,000 investment in Canada’s top pot stocks

Let’s look at a scenario where you invested $10,000 in some of the top pot stocks just before legalization took place, and what the value of those holdings would be today.

Oct. 16, 2018 Share Price Shares Owned Oct 16, 2020 Share Price Portfolio Value Loss
Canopy Growth $68.70 146 $23.47 $3,426.62 $6,573.38
Aphria $18.69 535 $6.13 $3,279.55 $6,720.45
OrganiGram $7.29 1372 $1.55 $2,126.60 $7,873.40
HEXO $8.23 1215 $0.99 $1,202.85 $8,797.15
Aurora Cannabis $13.98* 715 $0.44* $314.60 $9,685.40

*Price when factoring out the stock’s 12-for-1 reverse split.

Regardless of which Canadian pot stock you invested in two years ago, you’d likely have a big dent in your portfolio if you held on until now. Even the industry leaders at the time, Canopy Growth and Aurora Cannabis, have suffered significant losses in the years since legalization. Concerns surrounding profitability and sometimes even liquidity have put investors on edge. Even with a big investor like Constellation Brands backing Canopy Growth, that hasn’t been enough to make it a stable buy.

By no means does this mean that these stocks can’t recover from their significant declines, but investors should be very careful investing in what’s been an erratic industry in recent years. Promises of future growth are meaningless if companies aren’t able to deliver the results.

Should you steer clear of pot stocks?

For many conservative, risk-averse investors, the short answer to this question is definitely “yes.” Although lots of growth exists in the cannabis industry, it could look a whole lot different in the next few years. Consolidation is inevitable, as some cannabis companies may not have enough cash to stay afloat amid a pandemic and a recession. And with stock prices a fraction of what they were worth a few years ago, dipping into the equity markets to raise cash isn’t an attractive option anymore.

If you’re investing in cannabis, you need to be aware of the significant risks involved when doing so. There’s no guarantee that these stocks have stopped falling in value or that they’ll even be around in a few years.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands and OrganiGram Holdings. The Motley Fool recommends HEXO., HEXO., and OrganiGram Holdings.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »